trial

A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

NCTId NCT00567710
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 360 (estimated)
Sponsored by BioLineRx, Ltd.
Primary completion 2009-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
360 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-07
Primary completion
2009-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BL - 1020Risperidone

Sponsors

BioLineRx, Ltd.Lead Sponsor

Investigators

1
Yona Geffen, Ph.DStudy Director

Sites

1 total
Irving, United States

Linked catalysts

1
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi- — primary completion2009-07

Facts & assertions

4 sourced
Enrollment
360
Phase
PHASE2
Primary Completion Date
2009-07
Status
COMPLETED
relationships
The graph out of here
drug
BL - 1020
drug
Risperidone
drug
lead_sponsor
BioLineRx, Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yona Geffen, Ph.D
person